The trial evaluates THIO, a telomere-targeting agent, in combination with Regeneron (NASDAQ:REGN)'s cemiplimab, an immune checkpoint inhibitor, in patients who have not responded to at least two ...
As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...
In summary, MAIA Biotechnology’s recent updates regarding its Phase 2 THIO-101 trial demonstrate the company’s commitment to communicating significant developments in its oncology research ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...
Plus doux, mais devenant pluvieux. Des brouillards localement givrants sont encore d'actualité aux premières heures du jour sur le Grand-Est. Le matin, des précipitations éparses affectent la moitié ...
Anton Tiauw-Lok Tan’s Post Anton Tiauw-Lok Tan Retired Consultant Paediatrician and Lecturer MB, ChB, MRCP (UK), FRCPCH (UK), CCST (UK), DTMH ...
A new experience for me: Attending my first Annual Conference of the Austrian Paediatric Society in Salzburg and presenting 2 posters. Luckily my German kept me going.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback